FDA Puts Clinical Hold on uniQure's Hope B Trial

The following is an excerpt from a press release from uniQure. Read the update in its entirety.

Today uniQure announced a clinical hold by the U.S. Food and Drug Administration (FDA) in its phase III HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients.